Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry)

American Journal of Cardiology

Volumn 115, Issue 12, 2015, Pages 1655-1660

  O'Brien, Emily C ^a   Simon, DaJuanicia N ^a   Roe, Matthew T ^a   Wang, Tracy Y ^a   Peterson, Eric D ^a   Alexander, Karen P ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNSTABLE ANGINA PECTORIS; ANGINA, UNSTABLE; BLOOD; COMORBIDITY; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTER; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGINA, UNSTABLE; CHOLESTEROL, LDL; COMORBIDITY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84930180844     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.03.007     Document Type: Article

References (21)

1. J. Pekkanen, S. Linn, G. Heiss, C.M. Suchindran, A. Leon, B.M. Rifkind, and H.A. Tyroler Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 1990 1700 1707
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III) final report Circulation 106 2002 3143 3421
3. Scandinavian Simvastatin Survival Study Investigators, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
4. A.M. Tonkin, D. Colquhoun, J. Emberson, W. Hague, A. Keech, G. Lane, S. MacMahon, J. Shaw, R.J. Simes, P.L. Thompson, H.D. White, and D. Hunt Effects of pravastatin in 3260 patients with unstable angina pectoris: results from the LIPID study Lancet 356 2000 1871 1875
5. Heart Protection Study Investigators, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
6. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, and A.M. Skene Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
7. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, and E. Braunwald The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators N Engl J Med 335 1996 1001 1009
8. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, and R.G. Westendorp Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
9. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of Cardiology/American Heart Association Task Force on Practice guidelines Circulation 129 25 Suppl 2 2014 S1 S45
10. J. Afilalo, G. Duque, R. Steele, J.W. Jukema, A.J. de Craen, and M.J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis J Am Coll Cardiol 51 2008 37 45
11. J. Collinson, A. Bakhai, M.D. Flather, and K.A. Fox The management and investigation of elderly patients with acute coronary syndromes without ST elevation: an evidence-based approach? Results of the Prospective Registry of Acute Ischaemic Syndromes in the United Kingdom (PRAIS-UK) Age Ageing 34 2005 61 66
12. J.W. Hoekstra, C.V. Pollack Jr., M.T. Roe, E.D. Peterson, R. Brindis, R.A. Harrington, R.H. Christenson, S.C. Smith, E.M. Ohman, and W.B. Gibler Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative Acad Emerg Med 9 2002 1146 1155
13. K. Liang, and S. Zeger Longitudinal data analysis using generalized linear models Biometrika 73 1986 13 22
14. K.H. Cho, M.H. Jeong, Y. Ahn, Y.J. Kim, S.C. Chae, T.J. Hong, I.W. Seong, J.K. Chae, C.J. Kim, M.C. Cho, K.B. Seung, and S.J. Park Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox) Am J Cardiol 106 2010 1061 1068
15. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, B.A. Franklin, R.J. Gibbons, S.M. Grundy, L.F. Hiratzka, D.W. Jones, D.M. Lloyd-Jones, M. Minissian, L. Mosca, E.D. Peterson, R.L. Sacco, J. Spertus, J.H. Stein, and K.A. Taubert AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
16. D.T. Ko, M. Mamdani, and D.A. Alter Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox JAMA 291 2004 1864 1870
17. S.V. Arnold, M. Kosiborod, F. Tang, Z. Zhao, T.M. Maddox, P.L. McCollam, J. Birt, and J.A. Spertus Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction Circulation 129 2014 1303 1309
18. C. Fresco, A.P. Maggioni, S. Signorini, P.A. Merlini, P. Mocarelli, G. Fabbri, D. Lucci, M. Tubaro, M. Gattone, and C. Schweiger Variations in lipoprotein levels after myocardial infarction and unstable angina pectoris: the LATIN trial Ital Heart J 3 2002 587 592
19. D. Heldenberg, A. Rubinstein, O. Levtov, L. Berns, B. Werbin, and I. Tamir Serum lipids and lipoprotein concentrations during the acute phase of myocardial infarction Atherosclerosis 35 1980 433 437
20. R. Jackson, R. Scragg, R. Marshall, H. White, K. O'Brien, and C. Small Changes in serum lipid concentrations during first 24 hours after myocardial infarction Br Med J (Clin Res Ed) 294 1987 1588 1589
21. B. Pitt, J. Loscalzo, J. Ycas, and J.S. Raichlen Lipid levels after acute coronary syndromes J Am Coll Cardiol 51 2008 1440 1445